Search Results - "Brown, Michael P"

A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer by Mellor, James D, Brown, Michael P, Irving, Helen R, Zalcberg, John R, Dobrovic, Alexander

“…Antibody-dependent cellular cytotoxicity (ADCC) is a major mechanism of action of therapeutic monoclonal antibodies (mAbs) such as cetuximab, rituximab and…”
Get full text

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial by Falchook, Gerald S, Dr, Long, Georgina V, PhD, Kurzrock, Razelle, Prof, Kim, Kevin B, MD, Arkenau, Tobias H, PhD, Brown, Michael P, PhD, Hamid, Omid, MD, Infante, Jeffrey R, MD, Millward, Michael, MD, Pavlick, Anna C, MD, O’Day, Steven J, MD, Blackman, Samuel C, PhD, Curtis, C Martin, BA, Lebowitz, Peter, PhD, Ma, Bo, PhD, Ouellet, Daniele, PhD, Kefford, Richard F, Prof

“…Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish…”
Get full text

Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia by El Khawanky, Nadia, Hughes, Amy, Yu, Wenbo, Myburgh, Renier, Matschulla, Tony, Taromi, Sanaz, Aumann, Konrad, Clarson, Jade, Vinnakota, Janaki Manoja, Shoumariyeh, Khalid, Miething, Cornelius, Lopez, Angel F., Brown, Michael P., Duyster, Justus, Hein, Lutz, Manz, Markus G., Hughes, Timothy P., White, Deborah L., Yong, Agnes S. M., Zeiser, Robert

“…Successful treatment of acute myeloid leukemia (AML) with chimeric antigen receptor (CAR) T cells is hampered by toxicity on normal hematopoietic progenitor…”
Get full text

Targeting the dendritic cell-T cell axis to develop effective immunotherapies for glioblastoma by Gardam, Bryan, Gargett, Tessa, Brown, Michael P., Ebert, Lisa M.

“…Glioblastoma is an aggressive primary brain tumor that has seen few advances in treatments for over 20 years. In response to this desperate clinical need,…”
Get full text

Antibody drug conjugates: hitting the mark in pancreatic cancer? by Wittwer, Nicole L, Brown, Michael P, Liapis, Vasilios, Staudacher, Alexander H

“…Pancreatic cancer is one of the most common causes of cancer-related death, and the 5-year survival rate has only improved marginally over the last decade…”
Get full text

Aluminium Nanoparticles as Efficient Adjuvants Compared to Their Microparticle Counterparts: Current Progress and Perspectives by Nazarizadeh, Ali, Staudacher, Alexander H, Wittwer, Nicole L, Turnbull, Tyron, Brown, Michael P, Kempson, Ivan

“…Aluminium (Al) compounds are used as adjuvants in human and veterinary prophylactic vaccines due to their improved tolerability compared to other adjuvants…”
Get full text

Pembrolizumab 400 mg every 6 weeks as first-line therapy for advanced melanoma (KEYNOTE-555): Results from cohort B of an open-label, phase 1 study by Cohen, Graham, Rapoport, Bernardo, Chan, Sze W, Ruff, Paul, Arance, Ana, Mujika Eizmendi, Karmele, Houghton, Baerin, Brown, Michael P, Zielinski, Robert M, Muñoz Couselo, Eva, Lyle, Megan, Anderson, James R, Jain, Lokesh, de Alwis, Dinesh, Lala, Mallika, Akala, Omobolaji, Chartash, Elliot, Jacobs, Conrad

“…Intravenous pembrolizumab 400 mg every 6 weeks was approved across tumor types based on pharmacokinetic modeling, which showed exposures consistent with…”
Get full text

Plasma glycoproteomic biomarkers identify metastatic melanoma patients with reduced clinical benefit from immune checkpoint inhibitor therapy by Pickering, Chad, Aiyetan, Paul, Xu, Gege, Mitchell, Alan, Rice, Rachel, Najjar, Yana G, Markowitz, Joseph, Ebert, Lisa M, Brown, Michael P, Tapia-Rico, Gonzalo, Frederick, Dennie, Cong, Xin, Serie, Daniel, Lindpaintner, Klaus, Schwarz, Flavio, Boland, Genevieve M

“…The clinical success of immune-checkpoint inhibitors (ICI) in both resected and metastatic melanoma has confirmed the validity of therapeutic strategies that…”
Get full text

The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy by Yeo, Erica C F, Brown, Michael P, Gargett, Tessa, Ebert, Lisa M

“…Glioblastoma is the most common form of primary brain tumour in adults. For more than a decade, conventional treatment has produced a relatively modest…”
Get full text

Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma by Kollis, Paris M, Ebert, Lisa M, Toubia, John, Bastow, Cameron R, Ormsby, Rebecca J, Poonnoose, Santosh I, Lenin, Sakthi, Tea, Melinda N, Pitson, Stuart M, Gomez, Guillermo A, Brown, Michael P, Gargett, Tessa

“…Glioblastoma is the most common and aggressive form of primary brain cancer, with no improvements in the 5-year survival rate of 4.6% over the past three…”
Get full text

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer by Wittwer, Nicole L, Staudacher, Alexander H, Liapis, Vasilios, Cardarelli, Pina, Warren, Harriet, Brown, Michael P

“…BackgroundEmerging evidence suggests that the mechanism of chemotherapy-induced cell death may influence the antitumor immune response in patients with cancer…”
Get full text

APOMAB Antibody-Drug Conjugates Targeting Dead Tumor Cells are Effective In Vivo by Staudacher, Alexander H, Li, Yanrui, Liapis, Vasilios, Hou, Jeff Jia Cheng, Chin, David, Dolezal, Olan, Adams, Timothy E, van Berkel, Patrick H, Brown, Michael P

“…Antibody-drug conjugates (ADC) have revolutionized the field of cancer therapy. ADCs combine the high specificity of tumor-targeting monoclonal antibodies with…”
Get full text

GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma by Gargett, Tessa, Ebert, Lisa M, Truong, Nga T H, Kollis, Paris M, Sedivakova, Kristyna, Yu, Wenbo, Yeo, Erica C F, Wittwer, Nicole L, Gliddon, Briony L, Tea, Melinda N, Ormsby, Rebecca, Poonnoose, Santosh, Nowicki, Jake, Vittorio, Orazio, Ziegler, David S, Pitson, Stuart M, Brown, Michael P

“…BackgroundAggressive primary brain tumors such as glioblastoma are uniquely challenging to treat. The intracranial location poses barriers to therapy, and the…”
Get full text

Fc gamma receptor is not required for in vivo processing of radio- and drug-conjugates of the dead tumor cell-targeting monoclonal antibody, APOMAB by Staudacher, Alexander H., Liapis, Vasilios, Wittwer, Nicole L., Tieu, William, Lam, Hiu Chun, Leusen, Jeanette, Brown, Michael P.

“…The Fc region of a monoclonal antibody (mAb) can play a crucial role in its biodistribution and therapeutic activity. The chimeric mAb, chDAB4 (APOMAB®), which…”
Get full text

Midterm outcomes of femoral arteries after percutaneous endovascular aortic repair using the Preclose technique by Lee, W. Anthony, MD, Brown, Michael P., DO, Nelson, Peter R., MD, Huber, Thomas S., MD, PhD, Seeger, James M., MD

“…Objective Percutaneous access during endovascular aortic repair has been shown to be feasible and safe using a suture-mediated closure device (“Preclose”…”
Get full text

In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status by Reid, Paul, Wilson, Puthenparampil, Li, Yanrui, Marcu, Loredana G, Staudacher, Alexander H, Brown, Michael P, Bezak, Eva

“…Some head and neck squamous cell carcinomas (HNSCC) have a distinct aetiology, which depends on the presence of oncogenic human papilloma virus (HPV). Also,…”
Get full text

Vasculogenic mimicry structures in melanoma support the recruitment of monocytes by Tan, Lih Y., Cockshell, Michaelia P., Moore, Eli, Myo Min, Kay K., Ortiz, Michael, Johan, M. Zahied, Ebert, Brenton, Ruszkiewicz, Andrew, Brown, Michael P., Ebert, Lisa M., Bonder, Claudine S.

“…The progression of cancer is facilitated by infiltrating leukocytes which can either actively kill cancer cells or promote their survival. Our current…”
Get full text

Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma by Brown, Michael P, Ebert, Lisa M, Gargett, Tessa

“…Chimeric antigen receptor (CAR)‐T cell therapy is now approved in the United States and Europe as a standard treatment for relapsed/refractory B‐cell…”
Get full text

Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? by Staudacher, Alexander H, Brown, Michael P

“…Antibody drug conjugates (ADCs) employ the exquisite specificity of tumour-specific monoclonal antibodies (mAb) for the targeted delivery of highly potent…”
Get full text

Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436) by FALCHOOK, Gerald S, LONG, Georgina V, CHIN, Melvin T, O'DAY, Steven J, BLACKMAN, Samuel C, CURTIS, C. Martin, LEBOWITZ, Peter, BO MA, OUELLET, Daniele, KEFFORD, Richard F, KURZROCK, Razelle, KIM, Kevin B, ARKENAU, H.-Tobias, BROWN, Michael P, HAMID, Omid, INFANTE, Jeffrey R, MILLWARD, Michael, PAVLICK, Anna

“…Dabrafenib is a selective, potent ATP-competitive inhibitor of the BRAFV600-mutant kinase that has demonstrated efficacy in clinical trials. We report the…”
Get full text